

Heidi J Wehring

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/265658/publications.pdf>

Version: 2024-02-01

29
papers

487
citations

840776

11
h-index

677142

22
g-index

29
all docs

29
docs citations

29
times ranked

891
citing authors

#	ARTICLE	IF	CITATIONS
1	25-Hydroxyvitamin D and metabolic-related laboratory values in women with schizophrenia and hyperprolactinemia. <i>Journal of Psychiatric Research</i> , 2022, 151, 25-29.	3.1	1
2	Anti-aggressive effects of clozapine in involuntarily committed black patients with severe mental illness. <i>Schizophrenia Research</i> , 2022, 243, 163-169.	2.0	3
3	Feasibility and patient-reported satisfaction using a novel point-of-care novel fingerstick method for monitoring absolute neutrophil count (ANC) monitoring for clozapine at the point of care. , 2021, 33, 116-123.		1
4	L-Tetrahydropalmatine, a Novel Dopamine Antagonist, Fails to Improve Psychiatric Symptoms as Adjunctive Treatment for Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	0
5	Telepsychotherapy with youth at clinical high risk for psychosis: Clinical issues and best practices during the COVID-19 pandemic.. <i>Journal of Psychotherapy Integration</i> , 2020, 30, 304-331.	1.1	36
6	Treatments for the Prevention and Management of Suicide. <i>Annals of Internal Medicine</i> , 2020, 172, 167.	3.9	1
7	F88. CHILDHOOD SEXUAL ABUSE AND ADULT SEXUAL BEHAVIOR IN WOMEN WITH ANTIPSYCHOTIC-INDUCED HYPERPROLACTINEMIA. <i>Schizophrenia Bulletin</i> , 2019, 45, S287-S287.	4.3	0
8	T85. THE EFFECT OF ADJUNCT ARIPIPRAZOLE ON MEASURES OF TOBACCO USE AND CRAVING IN WOMEN WITH PSYCHOTIC DISORDERS. <i>Schizophrenia Bulletin</i> , 2019, 45, S236-S236.	4.3	0
9	S79. HEALTH STATUS OF PREMENOPAUSAL WOMEN WITH SCHIZOPHRENIA HAVING HYPERPROLACTINEMIA. <i>Schizophrenia Bulletin</i> , 2019, 45, S337-S337.	4.3	0
10	Effects of Cigarette Smoking and Clozapine Treatment on 20-Year All-Cause & Cardiovascular Mortality in Schizophrenia. <i>Psychiatric Quarterly</i> , 2019, 90, 351-359.	2.1	10
11	The Effect of Intranasal Oxytocin on Measures of Social Cognition in Schizophrenia: A Negative Report. <i>Journal of Psychiatry and Brain Science</i> , 2019, 4, .	0.5	4
12	Effects of intranasal oxytocin on satiety signaling in people with schizophrenia. <i>Physiology and Behavior</i> , 2018, 189, 86-91.	2.1	7
13	Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels. <i>Psychiatric Quarterly</i> , 2018, 89, 73-80.	2.1	14
14	Peripheral oxytocin and vasopressin are associated with clinical symptom severity and cognitive functioning in midlife women with chronic schizophrenia. <i>Schizophrenia Research</i> , 2018, 195, 409-411.	2.0	23
15	Peripheral Cortisol and Inflammatory Response to a Psychosocial Stressor in People with Schizophrenia. <i>Journal of Neuropsychiatry (Foster City, Calif)</i> , 2018, 02, .	0.1	14
16	Relationship of Interferon- β to Cognitive Function in Midlife Women with Schizophrenia. <i>Psychiatric Quarterly</i> , 2018, 89, 937-946.	2.1	12
17	Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 317-326.	1.4	25
18	Predictors of the Perception of Smoking Health Risks in Smokers With or Without Schizophrenia. <i>Journal of Dual Diagnosis</i> , 2017, 13, 29-35.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia. <i>Journal of Dual Diagnosis</i> , 2017, 13, 36-42.	1.2	7
20	Pharmacokinetics and Safety Assessment of<scp>l</scp>-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 151-160.	2.0	23
21	Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia. <i>Schizophrenia Research</i> , 2016, 172, 165-168.	2.0	21
22	Undiagnosed Lyme disease in adults with schizophrenia. <i>Schizophrenia Research</i> , 2015, 168, 579-580.	2.0	5
23	Risk-taking in schizophrenia and controls with and without cannabis dependence. <i>Schizophrenia Research</i> , 2015, 161, 471-477.	2.0	23
24	Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder. <i>Schizophrenia Research</i> , 2014, 152, 315-316.	2.0	5
25	Clinical characteristics of heavy and non-heavy smokers with schizophrenia. <i>Schizophrenia Research</i> , 2012, 138, 285-289.	2.0	19
26	Current status of clozapine in the United States. <i>Shanghai Archives of Psychiatry</i> , 2012, 24, 110-3.	0.7	7
27	Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection. <i>Journal of Central Nervous System Disease</i> , 2011, 3, JCNSD.S4091.	1.9	9
28	Cigarette Smoking and Mortality Risk in People With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 832-838.	4.3	130
29	Cardiovascular Disease Mortality in Patients With Chronic Schizophrenia Treated With Clozapine. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 304-311.	2.2	80